Addendum

Guselkumab (ulcerative colitis) – Addendum to Project A25-74

Status
Status: Commission completed
Project no.
A25-132
Last updated

Report documents

  1. Addendum

    Guselkumab (ulcerative colitis) Addendum to Project A25-74

    published on
    Document type
    PDF document, 244 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-132_en

Dossier assessment

Indication:

Adults with moderately to severely active ulcerative colitis

Result of dossier assessment:
  • Patients who have had an inadequate response with, lost response to, or were intolerant to conventional therapy: unchanged after addendum: added benefit not proven
  • Patients who have had an inadequate response with, lost response to, or were intolerant to a biologic agent (TNFα antagonist or integrin inhibitor or interleukin inhibitor): unchanged after addendum: added benefit not proven

Additional information

Federal Joint Committee (G-BA)

20-11-2025 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A25-132
Commission
Commission awarded on 07.10.2025 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Digestion, metabolism and hormones
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://doi.org/10.60584/A25-132_en

Connected Projects

  1. Dossier assessment

    Guselkumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-74
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form